Protalix BioTherapeutics Reports Q1 Earnings

Protalix BioTherapeutics has announced its first-quarter financial results, including a significant $25 million milestone payment received from Chiesi. This payment was triggered by a decision from the European Commission, marking a key development for the company. The company also hosted its scheduled earnings conference call, providing further details on its performance and outlook. Investors can access the full transcript of the call for in-depth information on the company's financial standing and strategic initiatives.